ONC
NASDAQBeOne Medicines Ltd.
News · 26 weeks77+119%
2025-12-282026-06-21
Mix6090d
- Insider34(57%)
- SEC Filings13(22%)
- Other11(18%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- INSIDERPresident and COO Wu Xiaobin sold $361,997 worth of American Depositary Shares (1,357 units at $266.76), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry sold $156,925 worth of American Depositary Shares (590 units at $265.98), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John sold $980,686 worth of American Depositary Shares (3,693 units at $265.55), closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident, Global Head of R&D Wang Lai sold $310,236 worth of American Depositary Shares (1,169 units at $265.39), closing all direct ownership in the company (SEC Form 4) (tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECSEC Form 144 filed by BeOne Medicines Ltd.144 - BeOne Medicines Ltd. (0001651308) (Subject)
- INSIDERPrincipal Accounting Officer Ball Titus B. was granted 31,213 units of Ordinary Shares and sold $43,467 worth of American Depositary Shares (169 units at $257.20), closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident, Global Head of R&D Wang Lai was granted 118,625 units of Ordinary Shares and sold $197,318 worth of American Depositary Shares (756 units at $261.00), closing all direct ownership in the company (SEC Form 4) (tax liability)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Financial Officer Rosenberg Aaron was granted 71,175 units of Ordinary Shares and sold $162,637 worth of American Depositary Shares (631 units at $257.74), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSVP, General Counsel Lee Chan Henry was granted 45,071 units of Ordinary Shares and sold $110,268 worth of American Depositary Shares (428 units at $257.63), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERPresident and COO Wu Xiaobin was granted 118,625 units of Ordinary Shares and sold $163,512 worth of American Depositary Shares (626 units at $261.20), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChair, Scientific Advisory Brd Wang Xiaodong was granted 99,892 units of Ordinary Shares, increasing direct ownership by 2% to 4,682,493 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERChief Executive Officer Oyler John was granted 177,931 units of Ordinary Shares and sold $501,355 worth of American Depositary Shares (1,949 units at $257.24), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Brandicourt Olivier was granted 18,980 units of Ordinary Shares, increasing direct ownership by 69% to 46,306 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Hooper Anthony C was granted 18,980 units of Ordinary Shares, increasing direct ownership by 29% to 83,720 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Mooney Elizabeth Fisher was granted 18,980 units of Ordinary Shares (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Dugan Margaret was granted 18,980 units of Ordinary Shares, increasing direct ownership by 35% to 73,164 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Sawyers Charles Lazelle was granted 18,980 units of Ordinary Shares, increasing direct ownership by 474,500% to 18,984 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Sharp Shalini was granted 18,980 units of Ordinary Shares, increasing direct ownership by 99% to 38,116 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERDirector Riva Alessandro was granted 18,980 units of Ordinary Shares, increasing direct ownership by 35% to 73,164 units (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERNew insider Sawyers Charles Lazelle claimed ownership of 4 units of Ordinary Shares and claimed ownership of 1,946 units of American Depositary Shares (SEC Form 3)3 - BeOne Medicines Ltd. (0001651308) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mooney Elizabeth Fisher3 - BeOne Medicines Ltd. (0001651308) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by BeOne Medicines Ltd.SCHEDULE 13D/A - BeOne Medicines Ltd. (0001651308) (Subject)
- INSIDERDirector Baker Bros. Advisors Lp was granted 37,960 units of Ordinary Shares (SEC Form 4)4 - BeOne Medicines Ltd. (0001651308) (Issuer)
- PRBeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton's tyrosine kinase (
ONC FAQ
6 questionsWhere does ONC stock trade?
BeOne Medicines Ltd. (ONC) is listed on NASDAQ.What sector and industry is ONC in?
BeOne Medicines Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BeOne Medicines Ltd. go public?
BeOne Medicines Ltd. (ONC) completed its IPO in 2016.What are analysts saying about ONC?
BeOne Medicines Ltd. has had 6 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-03-27.What companies are similar to ONC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ONC side-by-side with any of them on Quantisnow.How can I track ONC on Quantisnow?
Quantisnow aggregates BeOne Medicines Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONC to receive live email and push alerts on every new disclosure.